Case Background
Nektar Therapeutics sued Eli Lilly and Company in the U.S. District Court for the Northern District of California on August 7, 2023, accusing its former development partner of undermining rezpegaldesleukin (REZPEG), an experimental autoimmune drug, after Lilly acquired a competing eczema treatment. Judge James Donato presided over the case. Nektar is a San Francisco biopharmaceutical company. Lilly is an Indiana pharmaceutical company.
Cause
According to the first amended complaint, the companies signed a license agreement on July 23, 2017. Lilly took on responsibility for REZPEG’s clinical development. The agreement required Lilly to act in good faith and use “Commercially Reasonable Efforts.” It also provided milestone payments tied to Phase 3 progress and regulatory approvals.
Nektar alleged that Lilly’s interest waned after it acquired Dermira, Inc. in early 2020 for about $1.1 billion. That deal brought Lilly lebrikizumab, an antibody under development for eczema.
Nektar claimed Lilly miscalculated efficacy scores in Phase 1 eczema and psoriasis studies. Its formula allegedly capped the 72-point severity scale at 48. A September 2022 dermatology congress abstract reported about 66% eczema efficacy at the high dose. Nektar alleged the correct figure was about 83%.
Nektar also alleged that Lilly proposed an unreasonable Phase 2 eczema design and cited injection site reactions as a pretext. It further claimed Lilly let a Phase 2 lupus study become underpowered. On April 23, 2023, Lilly gave notice that it was terminating the agreement, after Nektar asked for REZPEG’s rights back.
Injury
Nektar alleged that the published data left analysts and investors lukewarm on REZPEG. It claimed the conduct delayed REZPEG’s development and eroded its first-mover advantage among interleukin-2 eczema therapies. Nektar said Lilly returned “a tarnished asset.” Nektar alleged that Lilly avoided making any milestone payment.
Damages
Nektar sought compensatory damages in an amount to be proven at trial. It also requested sums owed under the agreement, interest, costs, and attorneys’ fees. Nektar further sought an injunction requiring Lilly to return development materials.
Court orders show Nektar pursued a diminution-in-value theory. That calculation included the expected value of the milestone payments. On March 18, 2026, the Court denied Lilly’s summary judgment request challenging that theory. On July 27, 2026, the Court denied Lilly’s separate bid on the milestone payments. It ruled that Lilly’s termination, even at Nektar’s urging, was not an intervening act.
Key Arguments and Proceedings
Legal Representation
Plaintiff(s): Nektar Therapeutics
Counsel for Plaintiff(s): Kyle Kenneth Batter | Brendan Carroll | Christopher Tayback | David Morad Elihu | Derek Lawrence Shaffer | James A. Bieber | John Miguel McCauley | Joseph Mel Paunovich | Julia Sun Choe | Sarah Marianne Cork [Terminated: 05/06/2025] | Suong Nguyen | Thomas Parker | Yury Kapgan | Diane M. Doolittle
Defendant(s): Eli Lilly & Co.
Counsel for Defendant(s): Christopher William Keegan | Gabor Balassa | Mark Charles Holscher | Anna Terteryan [Terminated: 10/09/2025] | Cameron M. Bonk | Carolyn Jordan Weltman [Terminated: 07/18/2025] | Diana Marie Watral | Emma Scott | James F. Hurst | Keith Holt | Michael Joseph Hurvitz | Patrick John Weeks | Ryan Moorman
Key Arguments or Remarks by Counsel
Claims
Nektar’s original complaint asserted four claims. They included negligent misrepresentation and unfair competition under California Business and Professions Code Section 17200. The first amended complaint, filed May 3, 2024, narrowed the case to two counts.
The breach of contract count alleged that Lilly violated its good research practice and commercially reasonable efforts obligations. It cited the scoring error, the Phase 2 eczema design, and the lupus study’s conduct. It also alleged that Lilly failed to return all requested materials after termination.
The implied covenant count alleged that Lilly acted to delay or derail REZPEG’s approval. Nektar claimed the goal was to avoid milestone and royalty payments and give lebrikizumab a head start. It also alleged that Lilly terminated the agreement in bad faith.
Defense
Lilly denied all wrongdoing. In its March 2024 answer, Lilly admitted that a calculation error occurred in certain Phase 1 trials. It attributed the error to a third-party contract research organization that Nektar recommended and both parties agreed to hire. Lilly also admitted that Nektar’s revised calculations showed 83% eczema efficacy after 12 weeks.
Lilly’s counterclaims stated that it paid Nektar $150 million upfront. According to Lilly, REZPEG caused injection site reactions in 75% of eczema patients and 71% of psoriasis patients. Lilly said a joint steering committee requiring unanimous decisions oversaw development. It also said the parties jointly set the lupus trial endpoint.
Lilly asserted that the agreement acknowledged it might develop competing products. It also cited its at-will termination right. Lilly said it terminated at Nektar’s insistence because of the reaction data and the Phase 2 lupus results. It raised waiver and estoppel as affirmative defenses.
Lilly also counterclaimed for breach of contract and defamation over Nektar’s 2023 public statements. The Court later granted Lilly’s motion to dismiss both counterclaims with prejudice.
Jury Verdict
Trial began September 8, 2026, with each side limited to 12 hours of evidence. Before trial, the Court allowed Lilly to present testimony about Nektar’s failure to preserve evidence.
The jury returned its unanimous verdict on September 24, 2026. It found that Nektar did not prove Lilly breached the license agreement. It found that Lilly breached the implied covenant of good faith and fair dealing. The jury awarded Nektar $90 million.
On October 5, 2026, the Court entered judgment for Nektar for $90 million on the implied covenant claim. It entered judgment for Lilly on the breach of contract claim.
Post-trial Motions
The Court ordered a post-trial settlement conference and required each side to tender a specific settlement offer. Counsel for both sides filed declarations addressing that order on October 30, 2026.
In November 2026, Nektar moved to amend the judgment to add prejudgment interest. Lilly filed a renewed motion for judgment as a matter of law. Both motions are set for hearing on January 28, 2027. Lilly also filed an unopposed motion to stay execution without a supersedeas bond. Nektar filed an amended bill of costs. The docket showed no appeal as of November 18, 2026.
Court Documents:
Documents are available for purchase upon request at [email protected]



